Literature DB >> 25676366

Bone formation by human umbilical cord perivascular cells.

Sohtaro Kajiyama1, Yuko Ujiie1, Sumio Nishikawa1, Kohji Inoue2, Satoshi Shirakawa3, Nobuhiro Hanada4, Robert Liddell5, John E Davies6, Kasuhiro Gomi1.   

Abstract

We investigated the possibility of employing human umbilical perivascular cells (HUCPVCs) within the context of finding an alternative source of mesenchymal stromal cells (MSC) for bone tissue engineering. Since it has previously been reported that conditioned medium (CM) from osteogenic bone marrow (BM) MSCs can potentiate osteogenic differentiation in a secondary cell population, we also employed BM-MSCs to generate CM to stimulate osteogenesis in the HUCPVCs. The BM-MSCs were a commercially available immortalized human cell line. In vitro assays showed negligible levels of osteogenic gene expression in HUCPVCs compared to BM-MSC, but alkaline phosphatase was detected when HUCPVC were cultured in osteogenic medium in the presence of CM from BM-MSC. An in vivo assay employing a rat calvarial osteotomy defect, together with a collagen sponge scaffold, showed that HUCPVCs provided statistically significant bony repair compared to controls. BM-MSC loaded scaffolds were not statistically different from either controls or HUCPVCs. The addition of BM-MSC CM to HUCPVCs also produced no statistically significant difference to the bone formed by HUCPVCs alone. Our results demonstrate that the in vitro assays employed did not predict in vivo outcomes, and that the BM-MSC cell line employed, or CM from such cells, provided no osteogenic advantage over the use of HUCPVCs alone.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  bone; bone marrow cell line; osteotomy model; perivascular cells; umbilical cord

Mesh:

Year:  2015        PMID: 25676366     DOI: 10.1002/jbm.a.35396

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  5 in total

Review 1.  Perivascular cells and tissue engineering: Current applications and untapped potential.

Authors:  Elisa Avolio; Valeria V Alvino; Mohamed T Ghorbel; Paola Campagnolo
Journal:  Pharmacol Ther       Date:  2016-11-24       Impact factor: 12.310

2.  Early Intravenous Infusion of Mesenchymal Stromal Cells Exerts a Tissue Source Age-Dependent Beneficial Effect on Neurovascular Integrity and Neurobehavioral Recovery After Traumatic Cervical Spinal Cord Injury.

Authors:  Reaz Vawda; Anna Badner; James Hong; Mirriam Mikhail; Alam Lakhani; Rachel Dragas; Kristiana Xhima; Tanya Barretto; Clifford L Librach; Michael G Fehlings
Journal:  Stem Cells Transl Med       Date:  2019-03-26       Impact factor: 6.940

3.  Usefulness of Mesenchymal Cell Lines for Bone and Cartilage Regeneration Research.

Authors:  M Piñeiro-Ramil; C Sanjurjo-Rodríguez; R Castro-Viñuelas; S Rodríguez-Fernández; I M Fuentes-Boquete; F J Blanco; S M Díaz-Prado
Journal:  Int J Mol Sci       Date:  2019-12-13       Impact factor: 5.923

4.  Development and Characterization of Alkaline Phosphatase-Positive Human Umbilical Cord Perivascular Cells.

Authors:  Shun Nonoyama; Takeo Karakida; Risako Chiba-Ohkuma; Ryuji Yamamoto; Yuko Ujiie; Takatoshi Nagano; Yasuo Yamakoshi; Kazuhiro Gomi
Journal:  Cells       Date:  2021-11-04       Impact factor: 6.600

5.  Rapid Induction of Neural Differentiation in Human Umbilical Cord Matrix Mesenchymal Stem Cells by cAMP-elevating Agents.

Authors:  Atefeh Shahbazi; Majid Safa; Fatemeh Alikarami; Saeid Kargozar; Mohammad Hossein Asadi; Mohammad Taghi Joghataei; Mansoureh Soleimani
Journal:  Int J Mol Cell Med       Date:  2016-09-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.